Arcellx Inc (ACLX) Quote

ACLX under $100

ACLX new 52 week high

ACLX under $100

ACLX over $30

ACLX new 52 week high

ACLX new 52 week high

ACLX new 52 week high

Going beast mode into next week.

Nice correction coming here. New IPO at 16… company is flush with capital/cash. Moves coming and getting in now will pay off big IMHO.


Got in on the drop @average: 13.12 … 2 and 3 days ago.


$ACLX


GLTA!!



-TWYS

Net loss of $44M > no revenues! ( over 9 month period)

ACLX

Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share. With 33.54 million shares expected to be outstanding after the IPO, the expected pricing could value the company at up to $570.24 million. The stock is expected to list on the Nasdaq under the ticker symbol "ACLX." BofA Securities, SVB Leerink, Barclays and William Blair are the lead underwriters. The company recorded a net loss of $44.30 million on no revenue during the nine months ended Sept. 30, after a loss of $23.00 million on no revenue in the same period a year ago. Arcellx is looking to go public at a time of relative investor disdain for IPOs and biotechs, as the Renaissance IPO ETF IPO, -3.27% has plunged 37.2% over the past three months and the iShares Biotechnology ETF IBB, -1.39% has tumbled 19.8%, while the S&P 500 SPX, +0.31% has slipped 3.8%.